skip to main content
Idioma:

Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature

Dawsey, Scott J ; Campbell, Steven C ; Ornstein, Moshe C

Current oncology (Toronto), 2021-05, Vol.28 (3), p.1921-1926 [Periódico revisado por pares]

Switzerland: MDPI

Texto completo disponível

Citações Citado por
  • Título:
    Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature
  • Autor: Dawsey, Scott J ; Campbell, Steven C ; Ornstein, Moshe C
  • Assuntos: Carcinoma, Renal Cell - therapy ; Case Report ; Cytoreduction Surgical Procedures ; cytoreductive nephrectomy ; Humans ; Immunotherapy ; Kidney Neoplasms - surgery ; metastatic renal cell carcinoma ; Nephrectomy
  • É parte de: Current oncology (Toronto), 2021-05, Vol.28 (3), p.1921-1926
  • Notas: ObjectType-Case Study-2
    SourceType-Scholarly Journals-1
    ObjectType-Review-3
    content type line 23
    ObjectType-Feature-5
    ObjectType-Article-4
    ObjectType-Report-1
  • Descrição: The role and timing of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma receiving immunotherapy-based regimens is unclear. However, the ability to achieve a complete response for metastatic renal cell carcinoma likely requires a nephrectomy at some point during treatment. Here we present a case series of three patients with metastatic clear-cell renal-cell carcinoma who received front-line immunotherapy-based treatment and subsequently underwent a cytoreductive nephrectomy. All three patients had a complete response to therapy and have subsequently remained off systemic therapy for a median of 531 days (range, 476-602). We also review the limited literature in this setting and highlight ongoing clinical trials. Although the role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma receiving immunotherapy-based treatment is uncertain, a subset of patients will benefit from either an immediate or deferred cytoreductive nephrectomy. Ongoing trials are underway to further determine how to incorporate cytoreductive nephrectomy into the treatment paradigm for patients with metastatic renal cell carcinoma.
  • Editor: Switzerland: MDPI
  • Idioma: Inglês
Links
Voltar para lista de resultados
Ir para página anteriorAnterior Resultado  7 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.